Verona Pharma Plc - ADR
NASDAQ:VRNA
| Market Cap (Intraday) | 8.94B |
| Current PE | N/A |
| Forward PE | 617.06 |
| 2yr Forward PE | 139.87 |
| 10-Day MA | $102.05 |
| 50-Day MA | $86.39 |
| 200-Day MA | $59.50 |
Verona Pharma Plc - ADR Stock, NASDAQ:VRNA
3 More London Riverside, 3 More London Riverside, London, Greater London SE1 2RE
United Kingdom
Phone: +44.203.283.4200
Number of Employees: 209
Description
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.